Acteoside and martynoside exhibit estrogenic/antiestrogenic properties.
Acteoside and martynoside are plant phenylpropanoid glycosides exhibiting anticancer, cytotoxic and antimetastatic activities. We investigated their potential to activate estrogen receptor isoforms ERalpha and ERbeta in HeLa cells transfected with an estrogen response element (ERE)-driven luciferase (Luc) reporter gene and an ERalpha or ERbeta expression vector. Their estrogenic/antiestrogenic effects were also assessed in breast cancer cells (MCF7), endometrial cancer cells (Ishikawa) and osteoblasts (KS483), by measuring IGFBP3 levels, cell viability and number of mineralized nodules, respectively, seeking for a natural selective estrogen receptor modulator (SERM). Acteoside and martynoside antagonized both ERalpha and ERbeta (p<0.001), whereas they reversed the effect of E(2) mainly via ERalpha (p<0.001). Martynoside was a potent antiestrogen in MCF-7 cells, increasing, like ICI182780, IGFBP3 levels via the ER-pathway. In osteoblasts, martynoside induced nodule mineralization, which was abolished by ICI182780, implicating an ER-mediated mechanism. Furthermore, its antiproliferative effect on endometrial cells suggests that martynoside may be an important natural SERM. Acteoside was an antiestrogen in breast cancer cells and osteoblasts, without any effect on endometrial cells. Our study suggests that the nature is rich in selective ERalpha and ERbeta ligands, the discovery of which may lead to the development of novel neutraceutical agents.
Papoutsi
Zoi
Z
Department of Biological Chemistry, Medical School, University of Athens, 75 Mikras Asias Str., Goudi 11527, Athens, Greece.
Kassi
Eva
E
Mitakou
Sofia
S
Aligiannis
Nektarios
N
Tsiapara
Anna
A
Chrousos
George P
GP
Moutsatsou
Paraskevi
P
D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism; D002114:Calcinosis; D002470:Cell Survival / Q000187:drug effects; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000378:metabolism; D045166:Estradiol Congeners / Q000494:pharmacology*; D004965:Estrogen Antagonists / Q000494:pharmacology*; D047628:Estrogen Receptor alpha / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D047629:Estrogen Receptor beta / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D005260:Female; D005960:Glucosides / Q000494:pharmacology*; D006367:HeLa Cells; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000378:metabolism; D008024:Ligands; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism; D010636:Phenols / Q000494:pharmacology*; D020218:Response Elements; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology; D014162:Transfection; D014407:Tumor Cells, Cultured; D059808:Polyphenols
D045166:Estradiol Congeners; D004965:Estrogen Antagonists; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D005960:Glucosides; D018972:Insulin-Like Growth Factor Binding Protein 3; D008024:Ligands; D010636:Phenols; D020845:Selective Estrogen Receptor Modulators; C410405:martynoside; C058956:acteoside; D059808:Polyphenols